Gout
Conditions
Interventions
Intervention group:"Qizhi gout granules" decoction, one dose daily, divided into two administrations, taken orally.
Control group:Febuxostat tablet 20mg once a day
Sponsors
Fangshan Hospital Affiliated to Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily participate in this clinical research trial and sign the informed consent form. 2. Patients meeting the diagnostic criteria for gout as outlined in the "Guideline for Diagnosis and Treatment of Gout (2023 Edition)" issued by the Chinese Rheumatology Association, with a history of three years or more and currently in the chronic phase. 3. Conform to the diagnostic criteria for spleen deficiency, turbidity, and stasis syndrome. 4. No acute gout attacks occurred within the last two weeks. 5. Have not used uric acid excretion drugs, such as benzbromarone or probenecid, within the past two weeks. 6. Aged between 18 and 75 years, with no gender preference.
Exclusion criteria
Exclusion criteria: 1. Secondary gout: caused by conditions such as renal failure, diuretic use, or pyrazinamide; 2. Individuals with an allergic constitution, known or suspected allergies to the trial medication or its excipients; 3. Concurrent or secondary chronic kidney disease (such as uric acid nephropathy); 4. Coexistence of severe cardiovascular or cerebrovascular diseases, primary diseases of the blood, liver, or renal systems, or concurrent psychiatric disorders; 5. Concurrent acute infectious diseases, active or chronic phase of hepatitis B, decompensated cirrhosis, or active tuberculosis; 6. Unstable vital signs, severe electrolyte imbalances, or having undergone renal replacement therapy; 7. Coexistence of other diseases requiring long-term use of other traditional Chinese medicine formulations for four weeks or more; 8. Pregnant women, breastfeeding women, or women planning to become pregnant in the near future; 9. Participation in other clinical trials within the last three months or currently participating; 10. Researchers deem the individual unsuitable for participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood uric acid;24 hours uric acid excretion rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Urinary uric acid;Blood lipids;TCM syndrome score;Visual analogue scale for pain; | — |
Countries
China
Contacts
Public ContactBao Wujisiguleng
Fangshan Hospital, Beijing University of Chinese Medicine
Outcome results
None listed